Leaflet LYNPARZA 100mg film-coated tablets
Indicated for: cancer
Route of administration: oral
Substance: olaparib (PARP inhibitor)
ATC: L01XX46 (Antineoplastic and immunomodulating agents | Other antineoplastic agents)
This medicine may affect fertility.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Olaparib is a medication used for the treatment of certain types of cancer, such as ovarian, breast, or prostate cancer, associated with BRCA gene mutations. It is a poly(ADP-ribose) polymerase (PARP) inhibitor that interferes with DNA repair in cancer cells, leading to their death.
The medication is taken orally, usually twice daily, as directed by your doctor. It is important to follow the treatment regimen and undergo regular check-ups to monitor effectiveness and potential side effects.
Side effects may include nausea, fatigue, anemia, diarrhea, or, in rare cases, myelodysplastic syndrome.
Patients should inform their doctor about any other medications being used or pre-existing conditions to ensure the safe use of olaparib.
General data about LYNPARZA 100mg
- Substance: olaparib
- Date of latest medicines list: 01-06-2026
- Product code: W64660001
- Concentration: 100mg
- Pharmaceutical form: film-coated tablets
- Quantity: 56
- Product type: Original
- Price: 7281.69 RON
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for olaparib
Concentrations available for olaparib
- 100mg
- 150mg
- 50mg
